Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

7.61
+0.09501.26%
Volume:859.89K
Turnover:6.48M
Market Cap:1.66B
PE:-5.38
High:7.68
Open:7.50
Low:7.38
Close:7.51
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:0.63
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:3.20
PE(LYR):-5.35

Loading ...

Ocular Therapeutix to Present at ASRS Annual Meeting

Reuters
·
Jul 01

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

GlobeNewswire
·
Jul 01

Ocular Therapeutix is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 25

Chardan Raises Price Target on Ocular Therapeutix to $23 From $21, Keeps Buy Rating

MT Newswires Live
·
Jun 25

Ocular Therapeutix grants new SVP inducement awards of 85,000 stock options, 28,000 RSUs

Reuters
·
Jun 23

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 23

FDA Alignment on Axpaxli and New CFO Might Change The Case For Investing In Ocular Therapeutix (OCUL)

Simply Wall St.
·
Jun 22

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Jun 22

Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)

TIPRANKS
·
Jun 22

Ocular Therapeutix, Inc. : H.c. Wainwright Raises Target Price to $25 From $21

THOMSON REUTERS
·
Jun 18

Ocular Therapeutix Is Maintained at Outperform by Baird

Dow Jones
·
Jun 18

Ocular Therapeutix price target raised to $30 from $24 at Baird

TIPRANKS
·
Jun 18

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 18

Ocular Therapeutix Says FDA Aligned on Application for Axpaxli

Dow Jones
·
Jun 17

Ocular Therapeutix trading resumes

TIPRANKS
·
Jun 17

Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA

TIPRANKS
·
Jun 17

Ocular Therapeutix to resume trading at 9:15 am ET

TIPRANKS
·
Jun 17

Ocular Therapeutix says FDA aligns on AXPAXLI wet AMD NDA plan for Q4 2026 submission

Reuters
·
Jun 17

Ocular Therapeutix Inc - Sol-R Efficacy Data No Longer Part of Axpaxli Nda Submission Plan

THOMSON REUTERS
·
Jun 17

Ocular Therapeutix Inc - Plans to Submit Its Nda Under 505(B)(2) Pathway, With Potential to Accelerate Review Timeline by up to 60 Days

THOMSON REUTERS
·
Jun 17